Drug Search Results

Bentamapimod

Alternative Names: bentamapimod, pgl-5001, pgl5001, pgl 5001
Latest Update: 2024-02-01
Latest Update Note: PubMed Publication

Product Description

an inhibitor of c-Jun N-terminal kinase (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26335175/)

Mechanisms of Action: MAP2K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: PregLem
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bentamapimod

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Endometriosis

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
JADE	P2	Completed	Endometriosis	2014-05-06
JADE	P2	Completed	Endometriosis	2013-09-01

Recent News Events

Date	Type	Title
02/01/2024	PubMed	AS602801 treatment suppresses breast cancer metastasis to the brain by interfering with gap-junction communication by regulating Cx43 expression.
11/01/2022	PubMed	State of the art, new treatment strategies, and emerging drugs for non-hormonal treatment of endometriosis: a systematic review of randomized control trials.
09/09/2022	PubMed	Reduction of sporadic and neurofibromatosis type 2-associated vestibular schwannoma growth in vitro and in vivo after treatment with the c-Jun N-terminal kinase inhibitor AS602801.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions